NCT06322407Recruiting
Ultrasound-guided Stellate Ganglion Block for Treatment of Chronic Migraine in Adult
A Prospective, Randomized, Controlled, Blinded-endpoint Study to Evaluate the Efficacy and Safety of Stellate Ganglion Block for CM Treatment
Source: ClinicalTrials.gov · Last updated 17 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To assess the 6-months effects and safety of stellate ganglion block(SGB) for Chronic Migraine (CM) patients who failure to undergo preventive therapy and are seeking a more suitable non-pharmacological therapy.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 206 (estimated)
- First submitted
- 11 Mar 2024
- Start date
- 1 Jun 2024
- Primary completion date
- 1 Dec 2025
- Lead sponsor
- Beijing Tiantan Hospital
- Diseases
- Migraine
- NCT number
- NCT06322407
What you commit to
- Study type: Interventional
- Planned participants: 206
- From 1 Jun 2024 to the primary completion date, 1 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous SGB treatment；
- Neck anatomic structural changes (caused by radiotherapy or surgery);
Other illness
- History of other neurological disorders；
- History of severe cardiopulmonary, hepatic or renal dysfunction；
- History of allergies to any of the study drugs；
- Infection or mass near the puncture site；
- Psychological disorders;
Other
- BMI \<15 kg/m2 or \>35 kg/m2；
- Patients with chronic use of opioids；
- Preoperative coagulation abnormalities (activated partial thromboplastin time greater than 1.5 time normal value)；
- Pregnant or breast feeding;
- Refusal to sign informed consent.
Who the study is looking for
- Age from 18 to 65 years;
- Diagnosed with CM according to the International Classification of Headache Disorders, 3rd (ICHD-3) criteria \[Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1-211\].
- not received prior prophylactic migraine treatment or, due to lack of efficacy or tolerability, had failed or had not been suitable for up to three previous prophylactic treatments from the following: Metoprolol/propranolol, amitriptyline, and flunarizine.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Tiantan Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.